Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2015 1
2018 2
2019 1
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL, Kornblau SM, Lin CY, Sportoletti P, Martelli MP, Falini B, Goodell MA. Brunetti L, et al. Among authors: mezzasoma f. Cancer Cell. 2018 Sep 10;34(3):499-512.e9. doi: 10.1016/j.ccell.2018.08.005. Cancer Cell. 2018. PMID: 30205049 Free PMC article.
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
Pianigiani G, Gagliardi A, Mezzasoma F, Rocchio F, Tini V, Bigerna B, Sportoletti P, Caruso S, Marra A, Peruzzi S, Petito E, Spinozzi G, Shacham S, Landesman Y, Quintarelli C, Gresele P, Locatelli F, Martelli MP, Falini B, Brunetti L. Pianigiani G, et al. Among authors: mezzasoma f. Blood Adv. 2022 Nov 22;6(22):5938-5949. doi: 10.1182/bloodadvances.2022007563. Blood Adv. 2022. PMID: 36037515 Free PMC article.
IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML.
Perriello VM, Rotiroti MC, Pisani I, Galimberti S, Alberti G, Pianigiani G, Ciaurro V, Marra A, Sabino M, Tini V, Spinozzi G, Mezzasoma F, Morena F, Martino S, Salerno D, Ashby JF, Wingham B, Serafini M, Martelli MP, Falini B, Biondi A, Tettamanti S. Perriello VM, et al. Among authors: mezzasoma f. Blood Adv. 2023 Jun 27;7(12):2855-2871. doi: 10.1182/bloodadvances.2022008762. Blood Adv. 2023. PMID: 36521101 Free PMC article.
CD123 Is Consistently Expressed on NPM1-Mutated AML Cells.
Perriello VM, Gionfriddo I, Rossi R, Milano F, Mezzasoma F, Marra A, Spinelli O, Rambaldi A, Annibali O, Avvisati G, Di Raimondo F, Ascani S, Falini B, Martelli MP, Brunetti L. Perriello VM, et al. Among authors: mezzasoma f. Cancers (Basel). 2021 Jan 28;13(3):496. doi: 10.3390/cancers13030496. Cancers (Basel). 2021. PMID: 33525388 Free PMC article.
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML.
Gionfriddo I, Brunetti L, Mezzasoma F, Milano F, Cardinali V, Ranieri R, Venanzi A, Pierangeli S, Vetro C, Spinozzi G, Dorillo E, Wu HC, Berthier C, Ciurnelli R, Griffin MJ, Jennings CE, Tiacci E, Sportoletti P, Falzetti F, de Thé H, Veal GJ, Martelli MP, Falini B. Gionfriddo I, et al. Among authors: mezzasoma f. Leukemia. 2021 Sep;35(9):2552-2562. doi: 10.1038/s41375-021-01192-7. Epub 2021 Mar 2. Leukemia. 2021. PMID: 33654209 Free PMC article. Clinical Trial.
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Del Papa B, Baldoni S, Dorillo E, De Falco F, Rompietti C, Cecchini D, Cantelmi MG, Sorcini D, Nogarotto M, Adamo FM, Mezzasoma F, Silva Barcelos EC, Albi E, Iacucci Ostini R, Di Tommaso A, Marra A, Montanaro G, Martelli MP, Falzetti F, Di Ianni M, Rosati E, Sportoletti P. Del Papa B, et al. Among authors: mezzasoma f. Clin Cancer Res. 2019 Dec 15;25(24):7540-7553. doi: 10.1158/1078-0432.CCR-19-1009. Epub 2019 Oct 2. Clin Cancer Res. 2019. PMID: 31578228
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
Martelli MP, Rossi R, Venanzi A, Meggendorfer M, Perriello VM, Martino G, Spinelli O, Ciurnelli R, Varasano E, Brunetti L, Ascani S, Quadalti C, Cardinali V, Mezzasoma F, Gionfriddo I, Milano F, Pacini R, Tabarrini A, Bigerna B, Albano F, Specchia G, Vetro C, Di Raimondo F, Annibali O, Avvisati G, Rambaldi A, Falzetti F, Tiacci E, Sportoletti P, Haferlach T, Haferlach C, Falini B. Martelli MP, et al. Among authors: mezzasoma f. Blood. 2021 Dec 23;138(25):2696-2701. doi: 10.1182/blood.2021012732. Blood. 2021. PMID: 34343258 Free PMC article.
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation.
De Falco F, Del Papa B, Baldoni S, Sabatini R, Falzetti F, Di Ianni M, Martelli MP, Mezzasoma F, Pelullo M, Marconi P, Sportoletti P, Screpanti I, Rosati E. De Falco F, et al. Among authors: mezzasoma f. Cell Death Dis. 2018 Nov 26;9(12):1160. doi: 10.1038/s41419-018-1185-6. Cell Death Dis. 2018. PMID: 30478302 Free PMC article.
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
Martelli MP, Gionfriddo I, Mezzasoma F, Milano F, Pierangeli S, Mulas F, Pacini R, Tabarrini A, Pettirossi V, Rossi R, Vetro C, Brunetti L, Sportoletti P, Tiacci E, Di Raimondo F, Falini B. Martelli MP, et al. Among authors: mezzasoma f. Blood. 2015 May 28;125(22):3455-65. doi: 10.1182/blood-2014-11-611459. Epub 2015 Mar 20. Blood. 2015. PMID: 25795919 Free article.
11 results